ERBB2 and neoplasm: Trastuzumab, a humanized monoclonal anti-HER-2 antibody, aiming at the extracellular domain of HER-2 and blocking HER-2 to form allodimer to inhibit tumor, which has been approved to treat the HER-2 positive gastric cancer patients [11–13].